Background: We have done a systematic literature review about CRC Screening over 75 years old in order to update knowledge and make recommendations.

Methods: PUBMED database was searched in October 2021 for articles published on CRC screening in the elderly, and generated 249 articles. Further searches were made to find articles on the acceptability, efficacy, and harms of screening in this population, together with the state of international guidelines.

Results: Most benefit-risk data on CRC screening in the over 75 s derived from simulation studies. Most guidelines recommend stopping cancer screening at the age of 75. In private health systems, extension of screening up to 80-85 years is, based on the life expectancy and the history of screening. Screening remains effective in populations without comorbidity given their better life-expectancy. Serious adverse events of colonoscopy increase with age and can outweigh the benefit of screening. The great majority of reviews concluded that screening between 75 and 85 years must be decided case by case.

Conclusion: The current literature does not allow Evidence-Based Medicine propositions for mass screening above 75 years old. As some subjects over 75 years may benefit from CRC screening, we discussed ways to introduce CRC screening in France in the 75-80 age group. IRB: An institutional review board composed of members of the 2 learned societies (SOFOG and FFCD) defined the issues of interest, followed the evolution of the work and reviewed and validated the report.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817257PMC
http://dx.doi.org/10.1186/s12885-022-10418-5DOI Listing

Publication Analysis

Top Keywords

crc screening
20
screening
13
screening 75 years
8
crc
5
screen colorectal
4
colorectal cancer
4
cancer people
4
people aged
4
aged over?
4
over? systematic
4

Similar Publications

Cuproptosis, a newly identified form of cell death, has drawn increasing attention for its association with various cancers, though its specific role in colorectal cancer (CRC) remains unclear. In this study, transcriptomic and clinical data from CRC patients available in the TCGA database were analyzed to investigate the impact of cuproptosis. Differentially expressed genes linked to cuproptosis were identified using Weighted Gene Co-Expression Network Analysis (WGCNA).

View Article and Find Full Text PDF

Targeting NUCKS1 with a fragment of tRNA of Chinese yew for the treatment of colorectal cancer.

Noncoding RNA Res

April 2025

State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Avenida Wai Long, Taipa, Macau SAR, China.

Despite the discovery of numerous oncogenes in colorectal cancer (CRC), the development of associated drugs is limited, posing a significant challenge for CRC treatment. Identification of novel druggable targets is therefore crucial for the therapeutic development of CRC. Here, we report the first investigation on therapeutics targeting the potent oncogene NUCKS1 to suppress cancer progression.

View Article and Find Full Text PDF

Age, frequency, and strategy optimization for organized colorectal cancer screening: a decision analysis conducted in China for the years 2023-2038.

BMC Cancer

December 2024

Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, School of Basic Medicine, Peking Union Medical College, No. 5 Dongdansantiao Street, Dongcheng District, Beijing, 100005, China.

Background: The colorectal cancer mortality rate in China has exceeded that in many developing countries and is expected to further increase owing to multiple factors, including the aging population. However, the optimal policy for colorectal cancer screening is unknown.

Methods: We synthesized the most up-to-date data using a 12-state Markov model populated with a cohort of Chinese men and women born during 1949-1988, and evaluated 16 conventional and 40 risk-tailored schemes for colorectal cancer screening, considering possible combinations of age (starting at 40 + years and ending at 75 years), frequency, and strategy (standard colonoscopy, fecal immunochemical testing with colonoscopy if positive, or risk-tailored).

View Article and Find Full Text PDF

Background: Cancer remains a leading cause of mortality worldwide. A non-invasive screening solution was required for early diagnosis of cancer. Multi-cancer early detection (MCED) tests have been considered to address the challenge by simultaneously identifying multiple types of cancer within a single test using minimally invasive blood samples.

View Article and Find Full Text PDF

Colon capsule endoscopy: Can it contribute to green endoscopy?

World J Gastrointest Endosc

December 2024

Endoscopy Center, Aishinkai Nakae Hospital, Wakayama-shi 6408461, Japan.

Climate change due to sustained carbon dioxide (CO) emissions poses a serious threat to human existence, such as extreme weather events that must be addressed in all sectors of society. Gastrointestinal endoscopy is a healthcare sector that produces high levels of CO emissions. Colonoscopy (CS) is the gold standard for colorectal cancer (CRC) screening that reduces the number of CRC-related deaths.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!